Moderna Inc. [NASDAQ: MRNA] closed the trading session at $307.33 on 07/20/21. The day’s price range saw the stock hit a low of $292.00, while the highest price level was $342.51. The company report on July 20, 2021 that Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022.
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) have agreed to purchase and distribute an additional 50 million doses of Moderna’s COVID-19 vaccine and its updated variant booster vaccine candidate, if authorized, to begin delivery in 2022.
This new supply agreement is in addition to the prior agreement for 50 million doses in 2021 resulting in a total of 100 million doses for Japan. Moderna is responsible for the manufacture and supply of Moderna’s vaccine candidate, and Takeda, with the support of the MHLW and Moderna, is responsible for all import, local regulatory, development and distribution activities in Japan for these additional 50 million doses beginning in 2022.
The stocks have a year to date performance of 194.18 percent and weekly performance of 30.70 percent. The stock has been moved at 145.84 percent over the last six months. The stock has performed 54.29 percent around the most recent 30 days and changed 96.03 percent over the most recent 3-months.
If compared to the average trading volume of 10.17M shares, MRNA reached to a volume of 109382618 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Moderna Inc. [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $184.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on July 15, 2021. The new note on the price target was released on February 01, 2021, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise to $150, while Morgan Stanley analysts kept a Equal-Weight rating on MRNA stock. On December 16, 2020, analysts increased their price target for MRNA shares from 90 to 150.
The Average True Range (ATR) for Moderna Inc. is set at 17.47, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 40.95. The Price to Book ratio for the last quarter was 32.01, with the Price to Cash per share for the same quarter was set at 21.25. Price to Free Cash Flow for MRNA in the course of the last twelve months was 22.34 with Quick ratio for the last quarter at 1.30.
MRNA stock trade performance evaluation
Moderna Inc. [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 30.70. With this latest performance, MRNA shares gained by 54.29% in over the last four-week period, additionally plugging by 145.84% over the last 6 months – not to mention a rise of 271.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 79.75, with the RSI for the last a single of trading hit 82.75, and the three-weeks RSI is set at 76.84 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 207.70, while it was recorded at 282.74 for the last single week of trading, and 148.91 for the last 200 days.
Moderna Inc. [MRNA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of -94.99 and a Gross Margin at +95.12. Moderna Inc.’s Net Margin is presently recorded at -92.99.
Return on Total Capital for MRNA is now -37.14, given the latest momentum, and Return on Invested Capital for the company is -36.66. Return on Equity for this stock declined to -39.99, with Return on Assets sitting at -16.74. When it comes to the capital structure of this company, Moderna Inc. [MRNA] has a Total Debt to Total Equity ratio set at 9.28. Additionally, MRNA Total Debt to Total Capital is recorded at 8.49, with Total Debt to Total Assets ending up at 3.24. Long-Term Debt to Equity for the company is recorded at 8.09, with the Long-Term Debt to Total Capital now at 7.41.
Reflecting on the efficiency of the workforce at the company, Moderna Inc. [MRNA] managed to generate an average of -$574,665 per employee. Receivables Turnover for the company is 1.13 with a Total Asset Turnover recorded at a value of 0.18.Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.
Earnings per share (EPS) analysis for Moderna Inc. [MRNA] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.
Moderna Inc. [MRNA]: Insider Ownership positions
There are presently around $64,818 million, or 54.30% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 45,337,764, which is approximately 86.481% of the company’s market cap and around 2.50% of the total institutional ownership; BLACKROCK INC., holding 20,803,397 shares of the stock with an approximate value of $6.39 billion in MRNA stocks shares; and FLAGSHIP PIONEERING INC., currently with $6.33 billion in MRNA stock with ownership of nearly -33.333% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 470 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 43,159,908 shares. Additionally, 313 investors decreased positions by around 31,463,619 shares, while 93 investors held positions by with 136,282,794 shares. The mentioned changes placed institutional holdings at 210,906,321 shares, according to the latest SEC report filing. MRNA stock had 171 new institutional investments in for a total of 6,677,185 shares, while 95 institutional investors sold positions of 1,625,729 shares during the same period.